Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.

Wang J, Jain S, Coombes CR, Palmieri C.

Breast J. 2009 May-Jun;15(3):247-53. doi: 10.1111/j.1524-4741.2009.00713.x.

PMID:
19645779
3.

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.

Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R.

Breast Cancer Res Treat. 2007 Nov;106(1):105-12. Epub 2007 Feb 13.

PMID:
17295045
5.

Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.

Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA; North Central Cancer Treatment Group Trial N0032.

J Clin Oncol. 2006 Mar 1;24(7):1052-6.

PMID:
16505423
6.

Combination anastrozole and fulvestrant in metastatic breast cancer.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN.

N Engl J Med. 2012 Aug 2;367(5):435-44. doi: 10.1056/NEJMoa1201622.

7.

Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?

Safra T, Greenberg J, Ron IG, Ben-Yosef R, Inbar M, Sarid D, Yaal-Hahoshen N.

Isr Med Assoc J. 2008 May;10(5):339-43.

8.

Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre.

Catania C, Ascione G, Adamoli L, De Pas T, Medici M, Franceschelli L, Verri E, Magni E, Sanna G, Torrisi R, Goldhirsch A, Nolè F.

Breast Cancer Res Treat. 2007 Nov;106(1):97-103. Epub 2007 Jan 27.

PMID:
17260095
9.

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.

Robertson JF, Howell A, Gorbunova VA, Watanabe T, Pienkowski T, Lichinitser MR.

Breast Cancer Res Treat. 2005 Jul;92(2):169-74.

PMID:
15986127
10.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.

Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C.

Cancer. 2003 Jul 15;98(2):229-38.

11.

Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.

Steger GG, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, Gnant MF, Jakesz R, Zielinski CC.

Eur J Cancer. 2005 Nov;41(17):2655-61. Epub 2005 Oct 17.

PMID:
16230005
12.

Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.

Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel CL.

Breast Cancer Res Treat. 2004 Nov;88(2):103-8.

PMID:
15564793
14.

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5439-44.

15.

Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.

Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L; Trial 0020 Investigators; Trial 0021 Investigators.

Breast Cancer Res Treat. 2003 May;79(2):207-11.

PMID:
12825855
16.

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK.

J Clin Oncol. 2004 May 1;22(9):1605-13.

PMID:
15117982
17.

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B.

Ann Oncol. 2007 Jan;18(1):64-9. Epub 2006 Oct 9.

PMID:
17030543
18.

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M.

J Clin Oncol. 2008 Apr 1;26(10):1664-70. doi: 10.1200/JCO.2007.13.5822. Epub 2008 Mar 3.

PMID:
18316794
20.

[Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].

Martínez Marín V, Muñoz Martín AJ, Viñuela Benéitez MC, García Alfonso P, Alonso Muñoz A, Pérez Manga G.

Med Clin (Barc). 2009 Sep 19;133(10):371-4. doi: 10.1016/j.medcli.2008.11.029. Epub 2009 Apr 1. Spanish.

PMID:
19339025

Supplemental Content

Support Center